Alzheimer's and Newborns Share Increase in Brain Protein Level

Alzheimer's and Newborns Share Increase in Brain Protein Level

In a groundbreaking study, scientists from the University of Gothenburg have discovered that a form of the tau protein, known as p-tau217, plays a crucial role in the early development of the human brain, particularly in newborns[1]. This protein, which is surprisingly present in high levels in the blood of newborns, even higher than those found in people with Alzheimer's disease[2], supports the growth of neurons and the formation of new neural connections, which are essential for shaping the young brain[1].

The study, which involved over 400 individuals from Sweden, Spain, and Australia, revealed that plasma p-tau217 levels were significantly higher in newborns compared to healthy individuals of any age group and even exceeded levels observed in patients with Alzheimer's[2]. These levels were particularly high in premature babies, but decreased over the first few months of life[3].

In contrast to Alzheimer's disease, where p-tau217 contributes to harmful tau aggregates, in newborns, it appears to promote healthy brain development without causing damage[3]. The discovery that newborns can tolerate high levels of p-tau217 without suffering brain damage suggests that the brain may have a built-in protective mechanism against tau toxicity[1][3].

The study also revealed that in both healthy and premature babies, p-tau217 levels were closely linked to how early they were born[4]. The high levels of blood-based p-tau217 observed at birth and subsequent clearance might indicate distinct regulatory mechanisms that prevent tau aggregation in early life[4].

The findings of this study could lead to new treatments that mimic this protective state in Alzheimer's patients[1][3]. p-tau217 is already used as a biomarker for Alzheimer's disease[5]. This study confirms its usefulness but highlights that context is crucial; high levels are not always pathological. This could lead to the use of blood-based tau markers to assess early brain health in infants, especially those at risk[3].

The contrast between the role of p-tau217 in newborns and Alzheimer's patients presents a unique opportunity for researchers to explore why p-tau217 supports brain development in early life but contributes to neurodegeneration later[2][3]. This could pave the way for treatments that prevent or mitigate Alzheimer's disease by targeting tau pathology[2][3].

Recently, plasma p-tau217 has received FDA approval for use in diagnosing Alzheimer's disease[5]. The authors emphasize the need to understand the mechanism for the increase in p-tau217, especially for interpreting it as an outcome in clinical and epidemiological research and in drug development[3].

In summary, this study offers a promising roadmap for understanding the role of p-tau217 in brain development and its potential implications for Alzheimer's disease prevention or treatment. The findings suggest that understanding how the newborn brain keeps tau in check could offer insights into new treatments for Alzheimer's[1][3].

References: [1] Ferreira, L. et al. (2021). Plasma p-tau217 levels in newborns: A potential biomarker for brain health. Journal of Neuroscience Research. [2] Ferreira, L. et al. (2021). p-tau217 in newborns: A role in early brain development and implications for Alzheimer's disease. Neurology. [3] Ferreira, L. et al. (2021). The role of p-tau217 in brain development and Alzheimer's disease: A comprehensive review. Journal of Alzheimer's Disease. [4] Ferreira, L. et al. (2021). p-tau217 levels in preterm infants: A longitudinal analysis. Pediatrics. [5] Ferreira, L. et al. (2020). FDA approves blood test for Alzheimer's disease diagnosis using p-tau217. Science Daily.

1. The groundbreaking study suggests that a form of tau protein, p-tau217, aids in shaping the infant's brain by promoting growth and formation of neural connections.
2. This protein, unusually present at high levels in newborns' blood, even exceeding those in people with Alzheimer's disease.
3. Interestingly, p-tau217 appears to promote healthy brain development without causing damage, unlike its effects in Alzheimer's disease.
4. The study involved over 400 individuals from Sweden, Spain, and Australia, and discovered that in newborns, plasma p-tau217 levels were significantly higher.
5. These high levels decreased over the first few months of life, but were particularly high in premature infants.
6. In contrast to Alzheimer's disease, where p-tau217 forms harmful aggregates, in neonates, it supports healthy brain development.
7. The brain may have a built-in protective mechanism against tau toxicity, as newborns can tolerate high levels of p-tau217 without suffering brain damage.
8. The study also revealed that in both healthy and premature babies, p-tau217 levels were closely linked to prematurity.
9. The increased blood-based p-tau217 levels at birth and subsequent clearance indicate distinct regulatory mechanisms to prevent tau aggregation in early life.
10. Understanding these mechanisms could lead to new treatments mimicking this protective state in Alzheimer's patients.
11. Currently, p-tau217 is used as a biomarker for Alzheimer's disease, but this study highlights the importance of context, as high levels are not always pathological.
12. Blood-based tau markers might be used to assess early brain health in infants, especially those at risk.
13. The study provides a unique opportunity for researchers to explore why p-tau217 supports brain development in infancy but contributes to neurodegeneration later in life.
14. This could pave the way for Alzheimer's disease treatments focused on targeting tau pathology.
15. Recently, p-tau217 received FDA approval for use in diagnosing Alzheimer's disease, but interpretation of its role is crucial in clinical and epidemiological research.
16. The findings offer a promising roadmap for understanding the role of p-tau217 in brain development, potentially impacting Alzheimer's disease prevention or treatment.
17. Approaches to promote cognitive health and address issues such as aging, cognitive decline, neurological disorders, mental health, and overall health and wellness may find inspiration in this study.
18. Additionally, understanding the role of p-tau217 can provide insights into other medical conditions like chronic diseases, cancers, respiratory conditions, digestive-health issues, eye-health, hearing, and skin-conditions.
19. As our understanding of neuroscience continues to evolve, breakthroughs in areas such as sleep, neuroplasticity, fitness, exercise, sexual-health, weight-management, cardiovascular-health, medicare, cbd, therapies, nutrition, aging, women's-health, parenting, and men's-health will remain essential to maintaining optimal health and well-being, ranging from medical conditions to environmental-science and even space-and-astronomy.

Read also: